NYSE:ABTAbbott Laboratories Stock Price, Forecast & News

$91.47

+1.08 (+1.19 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$89.71

Now: $91.47▼

$91.54

50-Day Range

$79.45

MA: $90.79▼

$98.00

52-Week Range

$61.61

Now: $91.47▼

$100.00

Volume5.18 million shs

Average Volume7.31 million shs

Market Capitalization$161.80 billion

P/E Ratio45.96

Dividend Yield1.57%

Beta0.98

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Abbott Laboratories has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 14 buy ratings, 5 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $99.56, Abbott Laboratories has a potential upside of 8.8% from its current price of $91.47.
Amount of Analyst Coverage
Abbott Laboratories has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Abbott Laboratories has received 814 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Abbott Laboratories has received 677 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Abbott Laboratories has received 54.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote “Outperform” if you believe ABT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
Abbott Laboratories is a leading dividend payer. It pays a dividend yield of 1.57%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Abbott Laboratories has been increasing its dividend for 47 years.
Dividend Coverage
The dividend payout ratio of Abbott Laboratories is 44.44 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 39.89 % next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,359,524.00 in company stock.
Percentage Held by Insiders
Only 1.70% of the stock of Abbott Laboratories is held by insiders.
Percentage Held by Institutions
73.44% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Abbott Laboratories are expected to grow by 28.47% in the coming year, from $2.81 to $3.61 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Abbott Laboratories is 45.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.79.
Price to Earnings Ratio vs. Sector
The P/E ratio of Abbott Laboratories is 45.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.17.
Price to Earnings Growth Ratio
Abbott Laboratories has a PEG Ratio of 3.79. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Abbott Laboratories has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:ABT

Previous Symbol

CUSIP00282410

CIK1800

Webwww.abbott.com

Phone224-667-6100

Debt

Debt-to-Equity Ratio0.55

Current Ratio1.43

Quick Ratio1.01

Price-To-Earnings

Trailing P/E Ratio45.96

Forward P/E Ratio32.55

P/E Growth3.79

Sales & Book Value

Annual Sales$31.90 billion

Price / Sales5.07

Cash Flow$4.99 per share

Price / Cash Flow18.33

Book Value$17.70 per share

Price / Book5.17

Profitability

EPS (Most Recent Fiscal Year)$3.24

Net Income$3.69 billion

Net Margins11.15%

Return on Equity18.61%

Return on Assets8.61%

Miscellaneous

Employees107,000

Outstanding Shares1,768,840,000

Market Cap$161.80 billion

Next Earnings Date7/15/2020 (Estimated)

OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABT shares have increased by 17.1% and is now trading at $91.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Abbott Laboratories?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Abbott Laboratories.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, July 15th 2020. View our earnings forecast for Abbott Laboratories.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its earnings results on Thursday, April, 16th. The healthcare product maker reported $0.65 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.07. The healthcare product maker had revenue of $7.73 billion for the quarter, compared to analysts' expectations of $7.47 billion. Abbott Laboratories had a return on equity of 18.61% and a net margin of 11.15%. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 earnings per share. View Abbott Laboratories' earnings history.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Monday, April 20th. Investors of record on Friday, May 8th will be paid a dividend of $0.08 per share on Friday, May 29th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.35%. View Abbott Laboratories' dividend history.

What price target have analysts set for ABT?

20 equities research analysts have issued 1 year target prices for Abbott Laboratories' shares. Their forecasts range from $81.00 to $109.00. On average, they expect Abbott Laboratories' share price to reach $99.56 in the next year. This suggests a possible upside of 8.8% from the stock's current price. View analysts' price targets for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

News headlines about ABT stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abbott Laboratories earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news articles about the healthcare product maker a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAbbott Laboratories.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 19,570,000 shares, a drop of 8.8% from the April 30th total of 21,450,000 shares. Based on an average daily volume of 10,400,000 shares, the short-interest ratio is presently 1.9 days. Currently, 1.1% of the shares of the company are short sold. View Abbott Laboratories' Current Options Chain.

Who are some of Abbott Laboratories' key competitors?

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE), Masimo (MASI) and Insulet (PODD). View all competitors.

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T), Walt Disney (DIS), NVIDIA (NVDA), Cisco Systems (CSCO), Pfizer (PFE), Home Depot (HD), Intel (INTC) and Verizon Communications (VZ).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:

Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
Mr. Robert B. Ford, Pres & COO (Age 45)
Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.27%), Capital Research Global Investors (5.42%), State Street Corp (4.19%), Capital International Investors (3.15%), Wellington Management Group LLP (2.44%) and Massachusetts Financial Services Co. MA (1.55%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View institutional ownership trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Massachusetts Financial Services Co. MA, Fred Alger Management LLC, Primecap Management Co. CA, Sustainable Growth Advisers LP, Alliancebernstein L.P., Janus Henderson Group PLC, and Jennison Associates LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jared Watkin, John F Ginascol, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, and Sally E Blount. View insider buying and selling activity for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Polen Capital Management LLC, Veritas Asset Management LLP, Wellington Management Group LLP, BlackRock Inc., Fisher Asset Management LLC, Morgan Stanley, and Flossbach Von Storch AG. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift. View insider buying and selling activity for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $91.47.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $161.80 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 5/25/2020 by MarketBeat.com Staff